Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

A Message from Karen Kaucic, President of Evidera, on the COVID-19 Pandemic

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies

Venediktos Kapetanakis was featured in the Video Journal of Biomedicine to discuss his paper on assessment-schedule matching

Watch Now

Upcoming Webinar

Adjusting for Differences in Tumor Assessment Schedules in Indirect Comparisons of Progression-Free Survival for HTAs

Thursday, April 30, 2020 | 10:00AM EDT

Upcoming Webinar

Cutting-Edge Approaches to Support Clinical Development and Evidence Generation in the COVID-19 Era

Thursday April 2, 2020 | 1:00PM ET

Regulatory Rapporteur: The Expanding Role of Real-World Evidence in the Regulatory Environment

Mel Formica discusses the challenges regulators face as they seek to understand the acceptability of cutting-edge real-world data

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Endocrinology

Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States

J Manag Care Spec Pharm
March 2020

Oncology

Effectiveness of Durvalumab versus Chemotherapy in Metastatic Urothelial Cancer: An Observational, Indirect Comparison

J Comp Eff Res
March 2020

Rheumatology

Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus

Arthritis & Rheumatology
March 2020

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Market Access

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

Our work with clients, as well as through our partnerships with envelope-pushing, multi-stakeholder efforts such as the NEWDIGS LEAPS project and the Duke-Margolis RWE Collaborative, is helping to define the future of RWE in the healthcare space.

Debra A. Schaumberg, ScD, OD, MPH, Vice President, Real-World Evidence

Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.